COMBINATION ANTI-EPN1 AND ANTI-PD-L1 ANTIBODY THERAPIES

This invention relates to treating cancer by targeting the cell membrane-localized adaptor protein, Epsin-1 (EPN1), in combination with targeting one or more immune checkpoint proteins, including targeting programmed cell death-ligand 1 (PD-L1) and/or targeting Programmed cell death protein 1 (PD-1)...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	MORIN, Michael John, DOWLING, John P, ROBINSON, Matthew, SHEN, Fang
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	This invention relates to treating cancer by targeting the cell membrane-localized adaptor protein, Epsin-1 (EPN1), in combination with targeting one or more immune checkpoint proteins, including targeting programmed cell death-ligand 1 (PD-L1) and/or targeting Programmed cell death protein 1 (PD-1) La présente invention concerne le traitement du cancer par ciblage de la protéine adaptatrice localisée sur la membrane cellulaire, Epsine-1 (EPN1), en association avec le ciblage d'une ou de plusieurs protéines de point de contrôle immunitaire, comprenant le ciblage du ligand de mort cellulaire programmée 1 (PD-L1) et/ou le ciblage de la protéine de mort cellulaire programmée 1 (PD-1).